Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2006 1
2007 3
2009 1
2015 2
2016 3
2017 4
2018 10
2019 11
2020 24
2021 38
2022 27
2023 27
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer.
Boerrigter E, Overbeek JK, Benoist GE, Somford DM, Hamberg P, Tol J, Scholtes B, Willemsen AECAB, Buffart LM, Kessels RPC, Mehra N, van Oort IM, van Erp NP. Boerrigter E, et al. Among authors: mehra n. Eur Urol Oncol. 2024 Mar 13:S2588-9311(24)00057-9. doi: 10.1016/j.euo.2024.02.009. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38485614 Free article.
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Bosch D, van der Velden KJM, Oving IM, Wyndaele DNJ, Weijs LE, van Schelven WD, Oyen WJG, Te Beek ET, van de Luijtgaarden ACM, Somford DM, Nagarajah J, Hermsen R, Mehra N, Gerritsen WR, van der Doelen MJ, van Oort IM. Bosch D, et al. Among authors: mehra n. J Nucl Med. 2024 Apr 1;65(4):541-547. doi: 10.2967/jnumed.123.266654. J Nucl Med. 2024. PMID: 38423781
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.
Fonseca NM, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha AJ, Kollmannsberger C, Kwan EM, Parekh K, Schönlau E, Bernales CQ, Donnellan G, Ng SWS, Sumiyoshi T, Vergidis J, Noonan K, Finch DL, Zulfiqar M, Miller S, Parimi S, Lavoie JM, Hardy E, Soleimani M, Nappi L, Eigl BJ, Kollmannsberger C, Taavitsainen S, Nykter M, Tolmeijer SH, Boerrigter E, Mehra N, van Erp NP, De Laere B, Lindberg J, Grönberg H, Khalaf DJ, Annala M, Chi KN, Wyatt AW. Fonseca NM, et al. Among authors: mehra n. Nat Commun. 2024 Feb 28;15(1):1828. doi: 10.1038/s41467-024-45475-w. Nat Commun. 2024. PMID: 38418825 Free PMC article.
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.
Rijnders M, Nakauma-González JA, Robbrecht DGJ, Gil-Jimenez A, Balcioglu HE, Oostvogels AAM, Aarts MJB, Boormans JL, Hamberg P, van der Heijden MS, Szabados BE, van Leenders GJLH, Mehra N, Voortman J, Westgeest HM, de Wit R, van der Veldt AAM, Debets R, Lolkema MP. Rijnders M, et al. Among authors: mehra n. Nat Commun. 2024 Feb 14;15(1):1349. doi: 10.1038/s41467-024-45714-0. Nat Commun. 2024. PMID: 38355607 Free PMC article.
Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort.
Richters A, Robbrecht DGJ, Meijer RP, van der Heijden AG, Kiemeney LALM, van den Bosch J, Suelmann BBM, Özdemir BC; ProBCI Study Group; Mehra N, Aben KKH. Richters A, et al. Among authors: mehra n. Eur Urol Open Sci. 2023 Dec 20;59:50-54. doi: 10.1016/j.euros.2023.11.010. eCollection 2024 Jan. Eur Urol Open Sci. 2023. PMID: 38213646 Free PMC article.
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. Orme JJ, et al. Among authors: mehra n. Eur Urol Oncol. 2023 Dec 9:S2588-9311(23)00277-8. doi: 10.1016/j.euo.2023.11.014. Online ahead of print. Eur Urol Oncol. 2023. PMID: 38072760
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.
Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Agarwal N, Olmos D, Thiery-Vuillemin A, Özgüroğlu M, Mehra N, Matsubara N, Young Joung J, Padua C, Korbenfeld E, Kang J, Marshall H, Lai Z, Barnicle A, Poehlein C, Lukashchuk N, Hussain M. Mateo J, et al. Among authors: mehra n. J Clin Oncol. 2024 Feb 10;42(5):571-583. doi: 10.1200/JCO.23.00339. Epub 2023 Nov 14. J Clin Oncol. 2024. PMID: 37963304 Clinical Trial.
130 results